Cardiovascular benefit of gliflozins might be class effect

Improved cardiovascular outcomes in studies of people with type 2 diabetes on sodium-glucose co-transporter (SGLT2) inhibitors may reflect a class effect, an Australian review suggests.

The drugs were already known to reduce body weight and blood pressure. Now, trials are demonstrating improvements in cardiovascular endpoints, report the five clinicians who conducted the review.

Empagliflozin reduced a composite primary endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke by 14% compared with placebo in the EMPA-REG OUTCOME trial of people